医学
子宫内膜癌
肿瘤科
恶性肿瘤
内科学
靶向治疗
激素疗法
化疗
疾病
癌症
转移性乳腺癌
乳腺癌
作者
Sarah M. Temkin,Gini F. Fleming
标识
DOI:10.1177/107327480901600106
摘要
Endometrial cancer is the most common gynecologic malignancy. The majority of patients have disease confined to the uterus and have an excellent overall prognosis. However, subgroups of patients have advanced primary disease or recurrences following primary treatment.The management of metastatic disease is variable, depending on factors such as comorbidities, tumor grade, performance status, and prior treatments. Management options include hormonal therapy and cytotoxic chemotherapy, as well as targeted therapies that inhibit angiogenesis and the cellular signaling pathways involved in cell growth and proliferation. A comprehensive review of these treatments for metastatic endometrial cancer was conducted and is discussed.Hormonal therapy and cytotoxic chemotherapy have traditionally been used in the treatment of metastatic endometrial cancer. Advances in molecular biology have led to multiple potential targeted therapies to be used in the treatment of metastatic endometrial cancer.While several treatment modalities are now available to treat patients who present with metastatic endometrial cancer, overall prognosis remains poor.
科研通智能强力驱动
Strongly Powered by AbleSci AI